Medeon Biodesign (6499) reported revenue of NT$38 million for Oct 2026, +2.7% year on year and -83.6% from the previous month. Revenue for Jan–Oct 2026 was NT$570.9 million (+67.2% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 109 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$38 million | +2.7% | -83.6% |
| Sep 2026 | NT$231.5 million | +513.1% | +508.1% |
| Aug 2026 | NT$38.1 million | +29.5% | -10.3% |
| Jul 2026 | NT$42.4 million | +68.8% | +16.3% |
| Jun 2026 | NT$36.5 million | -7.1% | +10.5% |
| May 2026 | NT$33 million | -6.3% | -11.1% |
| Apr 2026 | NT$37.1 million | +3.4% | +2.8% |
| Mar 2026 | NT$36.1 million | -6.7% | -24.6% |
| Feb 2026 | NT$47.9 million | +32.3% | +58.3% |
| Jan 2026 | NT$30.3 million | +12.3% | -16.5% |
| Dec 2025 | NT$36.2 million | +49.6% | -13.0% |
| Nov 2025 | NT$41.7 million | +69.1% | +12.7% |
| Oct 2025 | NT$37 million | +29.8% | -2.1% |
| Sep 2025 | NT$37.8 million | +58.4% | +28.5% |
| Aug 2025 | NT$29.4 million | -53.6% | +16.9% |
| Jul 2025 | NT$25.1 million | +42.5% | -35.9% |
| Jun 2025 | NT$39.2 million | +77.6% | +11.4% |
| May 2025 | NT$35.2 million | +70.2% | -1.9% |
| Apr 2025 | NT$35.9 million | +73.2% | -7.2% |
| Mar 2025 | NT$38.7 million | +107.1% | +6.9% |
| Feb 2025 | NT$36.2 million | +153.7% | +34.3% |
| Jan 2025 | NT$27 million | +90.2% | +11.3% |
| Dec 2024 | NT$24.2 million | +10.9% | -1.7% |
| Nov 2024 | NT$24.6 million | +60.4% | -13.5% |
| Oct 2024 | NT$28.5 million | +56.0% | +19.5% |
Jan–Oct 2026 cumulative: NT$570.9 million (+67.2% YoY)
Other Biotech & Medical companies
Compare with peers: Medeon Biodesign vs PEC / Medeon Biodesign vs Lotus Pharm / Medeon Biodesign vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
累計營收較去年增長,係認列Cross-Seal資產讓與合約相關和解金、及CDMO事業體業務成長所致
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16